CN116138457A - Composite nutritional composition with depression symptom relieving effect - Google Patents
Composite nutritional composition with depression symptom relieving effect Download PDFInfo
- Publication number
- CN116138457A CN116138457A CN202211619749.5A CN202211619749A CN116138457A CN 116138457 A CN116138457 A CN 116138457A CN 202211619749 A CN202211619749 A CN 202211619749A CN 116138457 A CN116138457 A CN 116138457A
- Authority
- CN
- China
- Prior art keywords
- cfu
- lactobacillus
- depression
- composition
- mug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 230000000694 effects Effects 0.000 title claims abstract description 25
- 208000024891 symptom Diseases 0.000 title claims abstract description 24
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 15
- 239000002131 composite material Substances 0.000 title description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000006041 probiotic Substances 0.000 claims abstract description 32
- 235000018291 probiotics Nutrition 0.000 claims abstract description 32
- 235000015097 nutrients Nutrition 0.000 claims abstract description 28
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 26
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910052742 iron Inorganic materials 0.000 claims abstract description 16
- 239000011701 zinc Substances 0.000 claims abstract description 16
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 16
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000011669 selenium Substances 0.000 claims abstract description 15
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 15
- 235000011649 selenium Nutrition 0.000 claims abstract description 15
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 13
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 13
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 13
- 241000186840 Lactobacillus fermentum Species 0.000 claims abstract description 13
- 240000002605 Lactobacillus helveticus Species 0.000 claims abstract description 13
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims abstract description 13
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 13
- 241000194035 Lactococcus lactis Species 0.000 claims abstract description 13
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000014897 Streptococcus lactis Nutrition 0.000 claims abstract description 13
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 13
- 229960000304 folic acid Drugs 0.000 claims abstract description 13
- 239000011724 folic acid Substances 0.000 claims abstract description 13
- 235000019152 folic acid Nutrition 0.000 claims abstract description 13
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 13
- 229940012969 lactobacillus fermentum Drugs 0.000 claims abstract description 13
- 229940054346 lactobacillus helveticus Drugs 0.000 claims abstract description 13
- 241000124008 Mammalia Species 0.000 claims abstract description 6
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 5
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 5
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 5
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 5
- 235000013406 prebiotics Nutrition 0.000 claims description 15
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 12
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 12
- 230000000529 probiotic effect Effects 0.000 claims description 12
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 9
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 239000003674 animal food additive Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 35
- 238000002474 experimental method Methods 0.000 description 24
- 230000033001 locomotion Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000003542 behavioural effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000007267 depressive like behavior Effects 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010048259 Zinc deficiency Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000004531 Selenoprotein P Human genes 0.000 description 1
- 108010042443 Selenoprotein P Proteins 0.000 description 1
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 1
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a compound nutritional composition with a depression-like symptom relieving effect, which comprises probiotics, wherein the probiotics are selected from bifidobacterium longum, lactobacillus rhamnosus, lactobacillus casei, lactobacillus fermentum, lactobacillus helveticus and lactococcus lactis subspecies lactis, and also comprises nutrients, wherein the nutrients are selected from folic acid, vitamin B12, selenium, iron and zinc, and the nutrients and the probiotics are mutually combined to relieve the depression-like symptom of mammals. The compound nutritional composition with the function of relieving the depression-like symptoms can relieve the depression-like symptoms of mammals through the combination of probiotics and nutrients.
Description
Technical Field
The invention relates to a composition containing probiotics, in particular to a composite nutritional composition with the effect of relieving depression-like symptoms.
Background
In view of the fact that the occurrence mechanism of depression is not clear, depression patients lack effective drug treatment-the overall curative effect of the treatment group is less than 50%, the recurrence rate of the effective group is 40%, and the drug treatment inevitably causes adverse reactions.
The intestinal microbiota is known as the "second brain" of humans. The intestinal flora interacts not only with the enteric nervous system, but also with the central nervous system via neurological, neuroendocrine, neuroimmune and humoral connections. Among the many different probiotics, one class is known as mental probiotics, which has a beneficial effect on mental health. In addition, the influence of probiotics on the human nervous metabolism can be promoted by the probiotics, so that the normal growth of the probiotics is stimulated, and the intestinal-brain interaction is supported.
Thus, the prior art patent No. 2017800367686, entitled invention of a nutritional composition comprising probiotics for use in the prevention and/or treatment of anxiety and related disorders in mammals, discloses improving synaptic flexibility by increasing the content of at least one of a specific protein Arc (a protein associated with modulation of skeletal activity) and synaptic vesicle proteins present in the hippocampus of the brain. These proteins are better able to adapt in the case of fear, help to regulate the fear experienced during anxiety conditions, and help to prevent fear from occurring later in similar cases, thus achieving regulation in depression, however they do not take into account the important role of nutrients in the neuroendocrine system, the poor nutritional status caused by nutrient deficiency being related to the underlying pathology of behavioural health disorders, and therefore the efficacy of the composition is also somewhat inadequate.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a compound nutritional composition with better curative effect and depression symptom relieving effect.
In order to achieve the above purpose, the present invention provides the following technical solutions: a compound nutritional composition with effect of relieving depression-like symptoms comprises probiotics, wherein the probiotics are selected from bifidobacterium longum, lactobacillus rhamnosus, lactobacillus casei, lactobacillus fermentum, lactobacillus helveticus and lactococcus lactis subspecies, and also comprises nutrients, wherein the nutrients are selected from folic acid, vitamin B12, selenium, iron and zinc, and the nutrients and the probiotics are combined with each other to relieve the depression-like symptoms of mammals.
As a further improvement of the invention, a prebiotic is also included, selected from the group consisting of fructooligosaccharides, galactooligosaccharides.
As a further improvement of the present invention, maltodextrin is also included.
As a first improvement of the present invention,
wherein in the probiotic composition, 105-109 CFU/g of bifidobacterium longum, 105-1010 CFU/g of lactobacillus casei, 106-109 CFU/g of lactobacillus helveticus, 107-1010 CFU/g of lactobacillus rhamnosus, 107-109 CFU/g of lactobacillus fermentum and 105-108 CFU/g of lactococcus lactis subspecies lactis;
0.5-4 g of fructo-oligosaccharide and 0.5-4 g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 50-100 mug, vitamin B12.1-1.0 mug, selenium 0.5-2.5 mug, iron 1.0-5.0 mg and zinc 0.5-2.5 mg.
As a second modification of the present invention,
wherein in the probiotic composition, bifidobacterium longum is 107-1011 CFU/g, lactobacillus casei is 108-1011 CFU/g, lactobacillus helveticus is 109-1011 CFU/g, lactobacillus rhamnosus is 105-107 CFU/g, lactobacillus fermentum is 109-1012 CFU/g, lactococcus lactis subspecies lactis is 105-108 CFU/g;
4.0-8.0 g of fructo-oligosaccharide and 4.0-8.0 g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 100-400 mug, vitamin B12.0-1.2 mug, selenium 2.5-4.0 mug, iron 5.0-10.0 mg and zinc 2.5-5.0 mg.
As a third improvement of the present invention,
wherein in the probiotic composition, 105-108 CFU/g of bifidobacterium longum, 105-108 CFU/g of lactobacillus casei, 104-108 CFU/g of lactobacillus helveticus, 107-1010 CFU/g of lactobacillus rhamnosus, 104-107 CFU/g of lactobacillus fermentum and 109-1010 CFU/g of lactococcus lactis subspecies lactis;
2.0 to 6.0g of fructo-oligosaccharide and 2.0 to 6.0g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 20-60 mug, vitamin B12.8-1.5 mug, selenium 4.0-6.0 mug, iron 10.0-12.0 mg and zinc 1.0-4.5 mg.
The invention has the beneficial effects that zinc is taken as a trace element necessary for human body, plays an important role in maintaining the stability of cell membranes, participates in metabolism of more than 300 enzymes, and zinc in the human body mainly exists in brain, especially hippocampus and cerebral cortex. Serious zinc deficiency can lead to common symptoms of neurological diseases and depression, including immune dysfunction, dysphoria, mood changes and cognitive impairment, possibly associated with NMDA receptor antagonism. It was found that zinc deficiency resulted in an increased risk of developing depression, whereas zinc supplementation significantly improved depression-like behaviour. Selenium as an important component of glutathione peroxidase, thioredoxin reductase and selenoprotein P provides protection against lipid peroxidation and oxidative cell damage, and this anti-lipid peroxidation effect of selenium may play a role in its protection against depression. As an important mineral, iron is one of the essential nutrients for the human body, and has a variety of important functions in the body, including the function of iron-containing enzymes, synthesis of bile acids and steroid hormones, and signal control of certain neurotransmitters, such as serotonin and dopamine systems in the brain. In a meta-analysis, high iron intake was found to reduce the chance of depression. Iron deficiency has adverse effects on the psychological health of females and possibly causes depression, so that the effect of relieving depression-like symptoms can be effectively realized by adding nutrients.
Drawings
FIG. 1 is a flow chart of experimental animal feeding;
FIG. 2 is a graph showing the change in body weight and the food consumption rate of mice;
FIG. 3 is a box diagram of OFT experiment results;
FIG. 4 is a box-type diagram of EPM test results;
fig. 5 is a schematic diagram of the immobility time of mice in TST (a) and FST (B).
Detailed Description
The invention will be further described in detail with reference to examples of embodiments shown in the drawings.
The compound nutritional composition with the effect of relieving depression-like symptoms comprises probiotics, wherein the probiotics are selected from bifidobacterium longum, lactobacillus rhamnosus, lactobacillus casei, lactobacillus fermentum, lactobacillus helveticus and lactococcus lactis subspecies lactis, and also comprises nutrients, wherein the nutrients are selected from folic acid, vitamin B12, selenium, iron and zinc, and the nutrients and the probiotics are mutually combined to relieve the depression-like symptoms of mammals.
As an improved embodiment, the composition further comprises a prebiotic selected from the group consisting of fructooligosaccharides, galactooligosaccharides.
As an improved embodiment, maltodextrin is also included.
Specifically, the following example 1 is provided in this example;
wherein in the probiotic composition, 105-109 CFU/g of bifidobacterium longum, 105-1010 CFU/g of lactobacillus casei, 106-109 CFU/g of lactobacillus helveticus, 107-1010 CFU/g of lactobacillus rhamnosus, 107-109 CFU/g of lactobacillus fermentum and 105-108 CFU/g of lactococcus lactis subspecies lactis;
0.5-4 g of fructo-oligosaccharide and 0.5-4 g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 50-100 mug, vitamin B12.1-1.0 mug, selenium 0.5-2.5 mug, iron 1.0-5.0 mg and zinc 0.5-2.5 mg.
Specifically, this embodiment also has the following embodiment 2;
wherein in the probiotic composition, bifidobacterium longum is 107-1011 CFU/g, lactobacillus casei is 108-1011 CFU/g, lactobacillus helveticus is 109-1011 CFU/g, lactobacillus rhamnosus is 105-107 CFU/g, lactobacillus fermentum is 109-1012 CFU/g, lactococcus lactis subspecies lactis is 105-108 CFU/g;
4.0-8.0 g of fructo-oligosaccharide and 4.0-8.0 g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 100-400 mug, vitamin B12.0-1.2 mug, selenium 2.5-4.0 mug, iron 5.0-10.0 mg and zinc 2.5-5.0 mg.
Specifically, this embodiment also has the following embodiment 3;
wherein in the probiotic composition, 105-108 CFU/g of bifidobacterium longum, 105-108 CFU/g of lactobacillus casei, 104-108 CFU/g of lactobacillus helveticus, 107-1010 CFU/g of lactobacillus rhamnosus, 104-107 CFU/g of lactobacillus fermentum and 109-1010 CFU/g of lactococcus lactis subspecies lactis;
2.0 to 6.0g of fructo-oligosaccharide and 2.0 to 6.0g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 20-60 mug, vitamin B12.8-1.5 mug, selenium 4.0-6.0 mug, iron 10.0-12.0 mg and zinc 1.0-4.5 mg.
Experimental procedure and results
1. Design of animal experiment
48 male ICR mice (about 3 weeks old) of 18-22g were purchased, and after 1 week of adaptive feeding, the mice were randomly divided into 6 groups, respectively, a control group, a model group, a nutrient group, a probiotic group and a combination group, which were respectively subjected to gastric lavage (2.0 g/kg.bw/d) using different food formulations, and specific intervention measures are shown in Table 1. After 7 days of continuous intervention, except for the control group, physiological saline is injected into the abdominal cavity, other 5 groups are subjected to depression-like behavior induction by injecting LPS (0.5 mg/kg.bw/d) into the abdominal cavity, and the induction is carried out for 7 days, and intervention of different diet formulas is continued during the induction. Food intake was recorded daily during the experiment, and body weight was weighed and recorded every 3 days. The experiment was started on day 15, and the open field experiment, the overhead plus maze experiment, the tail suspension experiment, the forced swimming and the syrup preference experiment were performed, and the specific animal feeding flow is shown in fig. 2.
TABLE 1 animal intervention for different groups of experiments
2. Behavioural experiments
1) Open field experiment (OFT): reflecting the rejection response and the natural aversion to bright areas generated by mice when exploring new environments. The selected mice were placed in a well lit gray rectangular box (40 cm. Times.40 cm. Times.30 cm) and allowed to move freely within this area. The experiment was initially carried out by placing the mice facing a fixed corner in a small box, then recording the motion trajectories of each mouse with a camera within 6 minutes and generating digitized images, and analyzing the activity behavior for the next 4 minutes.
2) Overhead plus maze test (EPM): the device consisted of two opposing open arms (40 cm. Times.10 cm) and two opposing closed arms (40 cm. Times.10 cm) located 60cm from the ground. At the start of the experiment, mice were placed on a central platform and the activity of the mice (time and number of times the mice entered the open arms, etc.) was recorded during the 5 minute experiment.
3) Tail Suspension Test (TST): in the experiment, the tail of the mice (approximately 1 cm) was stuck with tape and hung in a position where they could not escape or catch the nearby surface (15 cm from the ground). The mice were observed for 6min and the immobility time of the mice was recorded for 4min after.
4) Forced Swimming Test (FST): during the measurement, the mice respond to unavoidable acute stress situations, alternating (floating) between struggling and resting. The animals were placed in a vertical glass cylinder (40 cm high, 15cm in diameter) filled with water at 22-24℃ (30 cm deep). The total duration of stress exposure was 6min, and the mice were left stationary for 4min after recording.
5) Sugar water preference experiment (SPT): the mice were responded to the absence of hedonia. The mice are placed in cages separately to adapt to 24 hours, two drinking bottles are arranged in the cages to respectively contain 1% sucrose solution and water, after water interruption for 12 hours, the two drinking bottles are respectively replaced by l% sucrose solution and water, after 12 hours, the two drinking bottles are respectively weighed (the water bottle is replaced after the middle 6 hours), and the syrup preference rate is calculated. Sugar water preference rate = sucrose solution consumption/(sucrose solution consumption + water consumption).
3. Experimental results
(1) Weight and food consumption rate
The mice were recorded for body weight change (once per 3 days) and food consumption (daily) before the end of the adaptation period to the beginning of the behavioural experiment, and as a result, no significant differences in body weight were found between the mice in the groups during the period (fig. 2A), while only day 9 in food intake were found between the control group and the model group, and no differences were found between the groups at the remaining time points (fig. 2B), indicating that the intervention treatment had no significant effect on both appetite and body weight of the animals.
(2) Behavioral outcome
1)OFT
After the experimental intervention and induction ended, the behavioural experiment was started. OFT was performed on day 15 of the experiment on each group of mice, and as a result, it was found that the number of times the mice in the model group entered the central region (fig. 3A), the residence time (fig. 3B), the movement path length (fig. 3C), and the ratio of the movement path length to the total path length (fig. 3D) were significantly different (P < 0.01), and significantly decreased (P < 0.05), compared to the control group, indicating that the mice after LPS treatment exhibited depression-like behavior. And after the application of the formulation intervention (nutrient, prebiotic, probiotic, or combination formulation), the depressive-like symptoms were alleviated for each group of mice (fig. 3A-D), fig. 3: (a) number of entries into the central region; (B) residence time in the central zone (seconds); (C) moving the path length (cm) in the central region; (D) The movement path in the central region is the ratio (%) of the total path length. The numbers of mice in each group were 6, with # P <0.05 and # P <0.0l indicating significant differences compared to the control group, and P <0.05 and P <0.0l indicating significant differences compared to the model group.
2) EPMOFT was completed and EPM was performed on day 16 of the experiment. As a result, it was found that the model group showed significant differences (P < 0.05) in the number of times of entry into the closed arm (fig. 4A), in the open arm movement distance (fig. 4B) and in the open arm movement time (fig. 4C) compared to the control group, and the control group had a reduced tendency in the open arm/closed arm movement time, indicating that the mice after LPS treatment also showed depression-like behavior; whereas the experimental group mice received various degrees of relief from depression-like symptoms after application of various diet formulas (fig. 4A-D), fig. 4: (a) number of times the closure arm is entered; (B) distance of movement in the open arm; (C) movement time in the open arm; (D) ratio of movement times in the open and closed arms. The numbers of mice in each group were 6, with # P <0.05 and # P <0.0l indicating significant differences compared to the control group, and P <0.05 and P <0.01 indicating significant differences compared to the model group;
3) TST and FST
Two behavioural experiments, TST and FST, were performed on days 17 and 18 respectively after EPM was completed to observe the immobility time of each group of experimental mice. During the experiment, the immobility time of the mice in the model group in TST and FST is significantly higher than that of the mice in the control group (figures 5B, P < 0.05) or has an increasing trend compared with that of the mice in the control group (figure 5A), which shows that the mice in the model group have depression-like behaviors under the influence of LPS, and the depression-like symptoms are significantly relieved under the intervention of various diet formulas (figures 5A and B), and particularly the intervention effect of the mice in the combined group is better. Figure 5 shows the immobility time of mice in TST (a) and FST (B). # P <0.01 indicates significant differences compared to the control group, whereas P <0.05 and P <0.01 indicate significant differences compared to the model group, with 6 mice per group.
From this, it can be seen that
a) Experiments respectively prove that probiotics, prebiotics and nutrients in the formula have anti-depression effects with different degrees when being singly interfered, the effects are better when the probiotics, the prebiotics and the nutrients are combined for intervention, the individual differences are smaller, and the anti-depression agent has universality for large crowds;
b) Compared with the antidepressant products on the market, the raw materials of the formula are convenient and easy to obtain;
c) As a class of food formulations, reference is mainly made to GB 14880-2012, which is safe and has no side effects.
Can be used as an adjuvant treatment food for people with depression or high risk group to improve or prevent depression. The above description is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above examples, and all technical solutions belonging to the concept of the present invention belong to the protection scope of the present invention. It should be noted that modifications and adaptations to the present invention may occur to one skilled in the art without departing from the principles of the present invention and are intended to be within the scope of the present invention.
Claims (6)
1. A complex nutritional composition having depression-like symptom alleviating effects comprising a probiotic selected from the group consisting of bifidobacterium longum, lactobacillus rhamnosus, lactobacillus casei, lactobacillus fermentum, lactobacillus helveticus, lactococcus lactis subspecies lactis, and characterized in that: the feed additive also comprises nutrients, wherein the nutrients are combinations of folic acid, vitamin B12, selenium, iron and zinc, and the nutrients and probiotics are mutually combined and are used for relieving depression-like symptoms of mammals.
2. The complex nutritional composition having depression-like symptom relieving effect according to claim 1, characterized in that: also included is a prebiotic selected from the group consisting of fructooligosaccharides, galactooligosaccharides, and combinations thereof.
3. The complex nutritional composition having depression-like symptom relieving effect according to claim 2, characterized in that: maltodextrin is also included.
4. A complex nutritional composition with depression-like symptom alleviating effect according to claim 2 or 3, characterized in that:
wherein in the probiotic composition, 105-109 CFU/g of bifidobacterium longum, 105-1010 CFU/g of lactobacillus casei, 106-109 CFU/g of lactobacillus helveticus, 107-1010 CFU/g of lactobacillus rhamnosus, 107-109 CFU/g of lactobacillus fermentum and 105-108 CFU/g of lactococcus lactis subspecies lactis;
0.5-4 g of fructo-oligosaccharide and 0.5-4 g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 50-100 mug, vitamin B120.1-1.0 mug, selenium 0.5-2.5 mug, iron 1.0-5.0 mg and zinc 0.5-2.5 mg.
5. A complex nutritional composition with depression-like symptom alleviating effect according to claim 2 or 3, characterized in that:
wherein in the probiotic composition, bifidobacterium longum is 107-1011 CFU/g, lactobacillus casei is 108-1011 CFU/g, lactobacillus helveticus is 109-1011 CFU/g, lactobacillus rhamnosus is 105-107 CFU/g, lactobacillus fermentum is 109-1012 CFU/g, lactococcus lactis subspecies lactis is 105-108 CFU/g;
4.0-8.0 g of fructo-oligosaccharide and 4.0-8.0 g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 100-400 mug, vitamin B121.0-1.2 mug, selenium 2.5-4.0 mug, iron 5.0-10.0 mg and zinc 2.5-5.0 mg.
6. A complex nutritional composition with depression-like symptom alleviating effect according to claim 2 or 3, characterized in that:
wherein in the probiotic composition, 105-108 CFU/g of bifidobacterium longum, 105-108 CFU/g of lactobacillus casei, 104-108 CFU/g of lactobacillus helveticus, 107-1010 CFU/g of lactobacillus rhamnosus, 104-107 CFU/g of lactobacillus fermentum and 109-1010 CFU/g of lactococcus lactis subspecies lactis;
2.0 to 6.0g of fructo-oligosaccharide and 2.0 to 6.0g of galacto-oligosaccharide in the prebiotic composition;
in the nutrient composition, folic acid 20-60 mug, vitamin B12 O.8-1.5 mug, selenium 4.0-6.0 mug, iron 10.0-12.0 mg and zinc 1.0-4.5 mg.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211619749.5A CN116138457A (en) | 2022-12-14 | 2022-12-14 | Composite nutritional composition with depression symptom relieving effect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211619749.5A CN116138457A (en) | 2022-12-14 | 2022-12-14 | Composite nutritional composition with depression symptom relieving effect |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116138457A true CN116138457A (en) | 2023-05-23 |
Family
ID=86339875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211619749.5A Pending CN116138457A (en) | 2022-12-14 | 2022-12-14 | Composite nutritional composition with depression symptom relieving effect |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116138457A (en) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103200830A (en) * | 2010-09-03 | 2013-07-10 | N·V·努特里奇亚 | Method and preparation for the treatment or prevention of anxiety or neurogenesis |
CN104548099A (en) * | 2015-01-12 | 2015-04-29 | 陶燃 | Anti-depression composition and application thereof |
WO2017047777A1 (en) * | 2015-09-18 | 2017-03-23 | 国立大学法人徳島大学 | Serotonin deficiency amelioration agent for after stress-load release |
US20170312232A1 (en) * | 2014-10-28 | 2017-11-02 | Medlab Ip Pty Ltd | Treatment for depression and depressive disorders |
CN108403724A (en) * | 2018-04-20 | 2018-08-17 | 北京斯利安药业有限公司 | A kind of composition and preparation method thereof of adjustable mood |
WO2018183355A1 (en) * | 2017-03-27 | 2018-10-04 | Research Institute At Nationwide Children's Hospital | Prebiotic formulations |
CN109310716A (en) * | 2016-07-01 | 2019-02-05 | 雀巢产品技术援助有限公司 | For preventing and/or treating the anxiety disorder of mammal and the alimentation composition comprising probiotics of associated disease |
CN111728111A (en) * | 2020-06-28 | 2020-10-02 | 武汉康复得生物科技股份有限公司 | Probiotic composition for relieving anxiety or depression and application thereof |
CN112999246A (en) * | 2021-01-22 | 2021-06-22 | 绍兴市第七人民医院 | Probiotic composition, and product and application thereof |
CN113583923A (en) * | 2021-09-28 | 2021-11-02 | 中国农业大学 | Probiotic composition and application thereof in preparation of medicine for treating constipation and depression |
EP3909589A1 (en) * | 2020-05-11 | 2021-11-17 | "Jantar" Wody Mineralne Sp z o.o. | Liquid probiotic-herbal preparation |
-
2022
- 2022-12-14 CN CN202211619749.5A patent/CN116138457A/en active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103200830A (en) * | 2010-09-03 | 2013-07-10 | N·V·努特里奇亚 | Method and preparation for the treatment or prevention of anxiety or neurogenesis |
US20170312232A1 (en) * | 2014-10-28 | 2017-11-02 | Medlab Ip Pty Ltd | Treatment for depression and depressive disorders |
CN104548099A (en) * | 2015-01-12 | 2015-04-29 | 陶燃 | Anti-depression composition and application thereof |
WO2017047777A1 (en) * | 2015-09-18 | 2017-03-23 | 国立大学法人徳島大学 | Serotonin deficiency amelioration agent for after stress-load release |
CN109310716A (en) * | 2016-07-01 | 2019-02-05 | 雀巢产品技术援助有限公司 | For preventing and/or treating the anxiety disorder of mammal and the alimentation composition comprising probiotics of associated disease |
WO2018183355A1 (en) * | 2017-03-27 | 2018-10-04 | Research Institute At Nationwide Children's Hospital | Prebiotic formulations |
CN108403724A (en) * | 2018-04-20 | 2018-08-17 | 北京斯利安药业有限公司 | A kind of composition and preparation method thereof of adjustable mood |
EP3909589A1 (en) * | 2020-05-11 | 2021-11-17 | "Jantar" Wody Mineralne Sp z o.o. | Liquid probiotic-herbal preparation |
CN111728111A (en) * | 2020-06-28 | 2020-10-02 | 武汉康复得生物科技股份有限公司 | Probiotic composition for relieving anxiety or depression and application thereof |
CN112999246A (en) * | 2021-01-22 | 2021-06-22 | 绍兴市第七人民医院 | Probiotic composition, and product and application thereof |
CN113583923A (en) * | 2021-09-28 | 2021-11-02 | 中国农业大学 | Probiotic composition and application thereof in preparation of medicine for treating constipation and depression |
Non-Patent Citations (2)
Title |
---|
刘薇娜: "《抑郁症的运动干预:基于动物模型的分子行为学依据》", 31 January 2017, 北京:知识产权出版社, pages: 21 - 23 * |
黄莹 等: "益生菌治疗抑郁症效果的meta 分析", 《职业与健康》, vol. 37, no. 7, 1 April 2021 (2021-04-01), pages 962 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9034314B2 (en) | Nutritional composition comprising probiotics and improving sleep patterns | |
US20210008130A1 (en) | Methods and compositions using bifidobacterium longum to treat or prevent depressive symptoms | |
EP3478306B1 (en) | Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and depression in a mammal | |
AU2019261707B8 (en) | Prebiotics for reducing the risk of obesity later in life | |
JP6329125B2 (en) | Stress relieving agent | |
EP2609814A1 (en) | Lactobacillus reuteri DSM 17938 for the development of cognitive function | |
CN116138457A (en) | Composite nutritional composition with depression symptom relieving effect | |
AU2014221272A1 (en) | A nutritional composition comprising probiotics and improving sleep patterns | |
KR20210102916A (en) | Probiotics for Cognitive and Mental Health | |
EP3344269A1 (en) | Methods and compositions using bifidobacterium longum to optimize breastfeeding | |
CN113332315B (en) | Application of bacteroides in preparation of product for preventing and treating Alzheimer disease | |
Tewari et al. | Probiotics and Gastrointestinal Health: Mechanism of Gastrointestinal Immunomodulation and Neuromodulation | |
EP4265297A1 (en) | Composition for improving inflammation of brain tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |